Comprehensive molecular testing revealed exceptionally high PD-L1 expression (90%) with negative next-generation sequencing for actionable mutations, establishing a diagnosis of stage IV NSCLC suitable for first-line pembrolizumab monotherapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.